A PYMNTS Company

US: Valeant Pharmaceutical’s CEO agrees to be deposed by Senate committee

By  |  April 13, 2016

Valeant Pharmaceuticals International Inc’s outgoing chief executive, Michael Pearson, consented to be deposed by a U.S. Senate committee later this month, after the panel threatened to hold him in contempt for failing to comply with a subpoena.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The Senate Special Committee on Aging said on Wednesday that Pearson will be deposed on April 18 ahead of an April 27 hearing that is part of its ongoing investigation into the rising prices of off-patent drugs, including two of Valeant’s heart medications.

    The deposition and hearing are coming at a critical time for the company, which is facing an onslaught of federal investigations into a wide variety of issues, from drug pricing and antitrust matters to its accounting and disclosures.

    The panel had been slated later on Wednesday to vote on whether to initiate contempt proceedings against Pearson, after he failed to show up last week for a deposition.

    The committee said it postponed the meeting after Pearson agreed to be interviewed under oath.

    Full Content: Financial Post

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.